CommonHealth dissolves professional shop

Share this article:

Physician-focused agency Adient has been closed, with staff and accounts, including Ortho-McNeil business, shifted to other units within WPP's CommonHealth family.

“We no longer felt it necessary to have five professional agencies,” said Matt Giegerich, CommonHealth president and CEO. “It also made sense for us. If the last decade was [about] splintering out, the new model is about pulling together. Looking for synergy is the new mode.”

Clients were advised of the dissolution of the 15-year-old agency gradually starting last summer, after the departure of erstwhile president Guy Dess. David Chapman, who had run Adient in an acting capacity, has since shifted focus to his other role of managing partner responsible for the four remaining professional agencies: Ferguson, Carbon, Noesis and Altum.

Brands in Ortho-McNeil's antibiotic franchise, including ceftobiprole and doripenem, were switched to Carbon. Listerine, Rogaine and other OTC brands, which Adient had handled for Pfizer before their purchase by Johnson and Johnson this year, are now handled by Noesis.

CommonHealth also made some recent restructuring moves in its consumer business, taking two prior groups—mass media, DTC shop Quantum and relationship-marketing unit Exchange—and combining them into a single agency, EvoLogue. EvoLogue is now the core agency of the CommonHealth Consumer Group, which may spin out other conflict shops under the same umbrella, a source said.

Among other highlights, CommonHealth launched offices in Paris and London.

Recent account wins included Abbott's dyslipidemia brands Niaspan, Advicor, TriCor and the pipeline compound ABT-335. Abbott decided to consolidate the franchise within a single agency after acquiring Niaspan and Advicor from Kos last year. The Advicor account was the only one in the franchise that CommonHealth had worked on prior to the consolidation. ABT-335 is in Phase III clinical trials for raising HDL, or “good,” cholesterol and reducing triglycerides.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...